Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Kidney Diseases (Basel, Switzerland)
|
December 13, 2023
Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
Haitao Zhang, Jingyuan Xie, Chuanming Hao, et al.
BMJ Open Diabetes Research & Care
|
May 30, 2023
Fecal microbiota transplantation ameliorates type 2 diabetes via metabolic remodeling of the gut microbiota in db/db mice
Lijuan Chen, Lin Guo, Susu Feng, et al.
Diabetes, Obesity & Metabolism
|
May 7, 2025
Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial
Lin Zhao, Feng Tao, Zhifeng Cheng, et al.
Life Metabolism
|
April 30, 2026
Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial
Congling Chen, Zhen Ying, Qi Tang, et al.
Diabetes, Obesity & Metabolism
|
April 3, 2019
Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial
Wenying Yang, Jianhua Ma, Guoyue Yuan, et al.
Current Medical Research and Opinion
|
September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
Linong Ji, Leili Gao, Zhifeng Cheng, et al.
Journal of Diabetes Investigation
|
November 21, 2025
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study
Leili Gao, Zhifeng Cheng, Guoqing Ma, et al.
Frontiers in Cellular and Infection Microbiology
|
April 11, 2022
Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients
Dafa Ding, Huijuan Yong, Na You, et al.
Kidney Diseases (Basel, Switzerland)
|
March 30, 2026
Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis
Ping Li, Yu An, Hongguang Zheng, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|
June 9, 2026
Neuroprotective role of Faecalibacterium prausnitzii-derived butyrate in diabetic gastrointestinal autonomic neuropathy
Lin Guo, Jie Li, Jiaming An, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Kidney Diseases (Basel, Switzerland)
|
December 13, 2023
Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
Haitao Zhang, Jingyuan Xie, Chuanming Hao, et al.
BMJ Open Diabetes Research & Care
|
May 30, 2023
Fecal microbiota transplantation ameliorates type 2 diabetes via metabolic remodeling of the gut microbiota in db/db mice
Lijuan Chen, Lin Guo, Susu Feng, et al.
Diabetes, Obesity & Metabolism
|
May 7, 2025
Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial
Lin Zhao, Feng Tao, Zhifeng Cheng, et al.
Life Metabolism
|
April 30, 2026
Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial
Congling Chen, Zhen Ying, Qi Tang, et al.
Diabetes, Obesity & Metabolism
|
April 3, 2019
Determining the optimal fasting glucose target for patients with type 2 diabetes: Results of the multicentre, open-label, randomized-controlled FPG GOAL trial
Wenying Yang, Jianhua Ma, Guoyue Yuan, et al.
Current Medical Research and Opinion
|
September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 study
Linong Ji, Leili Gao, Zhifeng Cheng, et al.
Journal of Diabetes Investigation
|
November 21, 2025
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study
Leili Gao, Zhifeng Cheng, Guoqing Ma, et al.
Frontiers in Cellular and Infection Microbiology
|
April 11, 2022
Prospective Study Reveals Host Microbial Determinants of Clinical Response to Fecal Microbiota Transplant Therapy in Type 2 Diabetes Patients
Dafa Ding, Huijuan Yong, Na You, et al.
Kidney Diseases (Basel, Switzerland)
|
March 30, 2026
Finerenone in Chinese Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELITY Subgroup Analysis
Ping Li, Yu An, Hongguang Zheng, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|
June 9, 2026
Neuroprotective role of Faecalibacterium prausnitzii-derived butyrate in diabetic gastrointestinal autonomic neuropathy
Lin Guo, Jie Li, Jiaming An, et al.
Page
of 6